Skip to content

Guerder Gentelet Robin

Active
Private limited companyfounded 20197 yrs activeZomerstraat 92, 1050 Elsene, BelgiumKBO/BCE: BE 0727.493.664

The computed 12-month bankruptcy probability of Guerder Gentelet Robin is 2.3% (moderate). The 2025 annual accounts show equity of €263k and a net result of €56k. Equity is growing by ~31.6% per year across the filed fiscal years. Its solvency ranks better than 91% of 18281 sector peers (fiscal year 2025). The company has been active since 2019 and the Belgian State Gazette contains no insolvency or warning signals.

Checked score

Score 2025
78 / 100
Excellent
The score weighs solvency, liquidity, profitability and financial development. Bankruptcy probability contributes 35%. Every signal that weighs is under Signals.
Axes · tick = 2024
Profitability91▲+14
Solvency100▲+9
Growth78=
Track record100
Bankruptcy probability, 12 months
2.3% Moderate
0%0.5%1.5%4%10%≥ 25%
Credit up to €20k at 30 days acceptable
Liquidity ample (current ratio 1.93 against 0.72 in 2024; short-term debt: 14.5% and cash: 15.4% of total assets), and 14.5% of the assets are financed with debt.
Credit advice for your own amount and term

Signals

Seven signals. The signal on the left, the evidence on the right.
lowers risk+raises riskneutral
raises risk · Limited track record
This company has not been active as long as an established one and statistically fails somewhat more often.
KBO · incorporation date
Age against the risk zone
elevated failure risk from 2 to 8 years 7 years 0 10 y
raises risk · Higher-failure-rate region
In this region companies fail more often than in the rest of the country.
KBO · registered office
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 47
Relative position
BE, all sectors
reference
Sector 47
higher
← fewer bankruptcies more bankruptcies →
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025
Solvency, return and age of the figures
Solvency
85.5%
Return on assets
18.1%
Age of the figures
9 mo
neutral · Filed after the deadline
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 31-08-2026, 31 days later. For context: 47% of the Belgian market files late and the whole 1-to-90-day band measures 2.0% abnormal legal state against a 1.66% average. We show this as a fact and do not score it.
NBB · 7 filings
Deviation from the deadline
2025
31 d late
2024
28 d late
2023
19 d late
2022
31 d late
2021
31 d late
2020
23 d late
2019
26 d late
← before the deadline after the deadline →
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven months
Position in the running window
23-09-2026 today31-12-2026 close31-07-2027 deadline
neutral · No strike-offs in the KBO publications
We found no ex-officio strike-off or cessation. Our series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
KBO publications · our coverage

Financials · fiscal year 2025, micro schema

Equity
€263k▲ 33.4%
2024 · €197k
2019: €50k 2020: €55k 2021: €168k 2022: €175k 2023: €178k 2024: €197k
2019 → 2025
Total assets
€307k▲ 3.5%
2024 · €297k
2019: €67k 2020: €77k 2021: €247k 2022: €250k 2023: €267k 2024: €297k
2019 → 2025
Net result
€56k▲ 186%
2024 · €19k
2019: €14k 2020: €5k 2021: €-1k 2022: €8k 2023: €2k 2024: €19k
2019 → 2025
Working capital
€41k
2024 · €-28k
2019: €47k 2020: €51k 2021: €-45k 2022: €-36k 2023: €-42k 2024: €-28k
2019 → 2025
Multi-year overview
Every figure with its change against the year before
▲ rise ▼ fall
Line20212022202320242025Trend
Equity€168k-€175k▲ 4.6%€178k▲ 1.2%€197k▲ 11.0%€263k▲ 33.4%
Operating result€2k-€14k▲ 590%€6k▼ 58.8%€28k▲ 369%€78k▲ 181%
Net result€-1k-€8k€2k▼ 72.6%€19k▲ 817%€56k▲ 186%
Turnover and EBIT margin not published: the micro schema does not require them.
Result per fiscal year
Operating resultNet result
€-20k€0€20k€40k€60k€80kOperating result 2021: €2k€2kNet result 2021: €-1k€-1kOperating result 2022: €14k€14kNet result 2022: €8k€8kOperating result 2023: €6k€6kNet result 2023: €2k€2kOperating result 2024: €28k€28kNet result 2024: €19k€19kOperating result 2025: €78k€78kNet result 2025: €56k€56k20212022202320242025
After the dip in 2023 the operating result has climbed two years in a row; 2025 is 181% above 2024 and is the highest result in the available series.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €307k
Fixed assets €221k▼ 1.6%
Current assets €86k▲ 19.4%
Equity and liabilities €307k
Equity €263k▲ 33.4%
Debt €45k▼ 55.4%
The debt ratio falls from 33.7% to 14.5%. Equity is higher and debt is lower.
Key figures and ratios
2025 value · change against 2024
EBITDA
€82k
2024 · €30k
Cash flow
€60k
2024 · €22k
Solvency
85.5%
2024 · 66.3%
Current ratio
1.93
2024 · 0.72
Quick ratio
1.93
2024 · 0.72
Debt / equity
0.17
2024 · 0.51
ROE
21.2%
2024 · 9.9%
ROA
18.1%
2024 · 6.6%
Interest coverage
229.88
2024 · 42.49
Debt
€45k
2024 · €100k
Debt ≤ 1 year
€45k
2024 · €100k
Income taxes
€22k
2024 · €8k
Green means a favourable move, even when the figure itself falls: as with debt or debt / equity.
Filed annual accounts
As filed with the NBB · 2025 against 2024
Balance sheet Code20242025
Assets
Total assets20/58€297k€307k
Fixed assets21/28€225k€221k
Tangible fixed assets22/27€15k€11k
Plant, machinery and equipment23€792€1k
Furniture and vehicles24€11k€8k
Other tangible fixed assets26€3k€2k
Financial fixed assets28€210k€210k=
Current assets29/58€72k€86k
Amounts receivable within one year40/41€53k€36k
Trade receivables40€43k€28k
Other amounts receivable41€10k€8k
Cash at bank and in hand54/58€19k€47k
Deferred charges and accrued income490/1-€2k
Equity and liabilities
Total equity and liabilities10/49€297k€307k
Equity10/15€197k€263k
Contributions10/11€150k€160k
Profit (loss) carried forward14€47k€103k
Amounts payable17/49€100k€45k
Amounts payable within one year42/48€100k€45k
Trade debts44€8k€5k
Suppliers440/4€8k€5k
Advances received on contracts in progress46€20k-
Taxes, remuneration and social security45€12k€7k
Taxes450/3€12k€7k
Other amounts payable47/48€60k€33k
Income statement Code20242025
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€2k€5k
Other operating charges640/8€1k€186
Gross operating margin9900€31k€83k
Operating profit (loss)9901€28k€78k
Financial charges65/66B€706€359
Recurring financial charges65€706€359
Profit (loss) for the period before taxes9903€27k€78k
Income taxes67/77€8k€22k
Profit (loss) for the period9904€19k€56k
Profit (loss) for the period to be appropriated9905€19k€56k
Appropriation of the result
Profit (loss) to be appropriated9906€47k€103k
Profit (loss) brought forward from the previous period14P€28k€47k

The notes to these accounts (6 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.

Download as CSV

Timeline · acts, filings and financial milestones

Next filing, fiscal year 2026, expected by 31-07-2027
2026
31-08
NBB filing Annual accounts filed
fiscal year 2025 · micro schema · 31 days late
2025
31-12
Financial Highest result since 2019net €56k ▲186%
Operating result €78k, net result €56k, both a record.
31-12
Financial Liquidity triplescurrent ratio 1.93
Current ratio from 0.72 to 1.93; short-term debt falls from €100k to €45k.
31-12
Financial Equity above €200kEq €263k ▲33.4%
4 profitable years in a row build equity to €263k.
28-08
NBB filing Annual accounts filed
fiscal year 2024 · micro schema · 28 days late
2024
19-08
NBB filing Annual accounts filed
fiscal year 2023 · micro schema · 19 days late
2023
31-08
NBB filing Annual accounts filed
fiscal year 2022 · micro schema · 31 days late
2022
31-12
Financial Back to profitnet €8k
Net result €8k after one loss-making year.
31-08
NBB filing Annual accounts filed
fiscal year 2021 · micro schema · 31 days late
2021
31-12
Financial Weakest financial yearnet €-1k ▼121%
Net result drops to €-1k, the lowest in the series; recovery starts the following year.
31-12
Financial Equity above €150kEq €168k ▲207%
Equity rises from €55k to €168k.
23-08
NBB filing Annual accounts filed
fiscal year 2020 · micro schema · 23 days late
2020
26-08
NBB filing Annual accounts filed
fiscal year 2019 · micro schema · 26 days late
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.

Directors · office · real estate

Directors
1 act for this company is in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Elsene · 1 establishment unit since 2019
establishment The establishment unit on the map
Cannot be placed on the map

This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.

Zomerstraat 921050 Elsene
Ground area
752 m²
Building footprint
521 m²
Volume, LiDAR
4,842 m³
Parcel 21445C0268/00C006, Brussels · tallest building 13.3 m, ±4 floors. Linked by address, not a title deed.
1 establishment unit
Guerder Gentelet Robin
Zomerstraat 92, 1050 ElseneManufacture of basic pharmaceutical products and pharmaceutical preparations
since 20192.289.518.318
1 parcel
Brussels 1 (100%)
Parcel (capakey) Region Area Buildings Height / fl.
21445C0268/00C006 Brussels 752 m² 1 · 521 m² 13.3 m · 4 fl.
Linked by address, not proof of ownership
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.

Similar companies · same sector, comparable size

Of 5,222 companies in sector 47730 we hold annual accounts for 3,861. 3,526 are within a factor 10 of this equity.See the whole sector

Company data · Crossroads Bank

Identification
Legal formPrivate limited company
Founded24-05-2019
Fiscal year end31-12
Abbreviation FR GGR
Activities, NACEBEL
47730Retail sale of pharmaceutical products
21100Manufacture of basic pharmaceutical products and pharmaceutical preparations
21209Manufacture of basic pharmaceutical products and pharmaceutical preparations
47740Retail trade
47741Retail sale of medical and orthopaedic goods, excluding prescription glasses and lenses
Sources
Crossroads Bank for EnterprisesNational Bank · 7 filingsAddress and cadastre registers

Data from official sources, last processed on 23-09-2026. Scores and ratios are computed by Checked and are not a credit decision.